A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis

Trial Profile

A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; Mayne Pharma
  • Most Recent Events

    • 25 May 2017 Phase has changed from 3 to 1 and patient number has also changed fron180 to 75.
    • 18 May 2017 Planned number of patients changed from 180 to 75.
    • 23 Oct 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board, IRB00009517).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top